Eliem Therapeutics (ELYM) Competitors $1.88 -0.12 (-6.00%) As of 10/14/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ELYM vs. ENTA, ZURA, FENC, TRDA, CRBU, CLLS, SLS, BDTX, SAVA, and EPRXShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Enanta Pharmaceuticals (ENTA), Zura Bio (ZURA), Adherex Technologies (FENC), Entrada Therapeutics (TRDA), Caribou Biosciences (CRBU), Cellectis (CLLS), SELLAS Life Sciences Group (SLS), Black Diamond Therapeutics (BDTX), Cassava Sciences (SAVA), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry. Eliem Therapeutics vs. Its Competitors Enanta Pharmaceuticals Zura Bio Adherex Technologies Entrada Therapeutics Caribou Biosciences Cellectis SELLAS Life Sciences Group Black Diamond Therapeutics Cassava Sciences Eupraxia Pharmaceuticals Eliem Therapeutics (NASDAQ:ELYM) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations. Do institutionals and insiders believe in ELYM or ENTA? 69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 13.9% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is ELYM or ENTA more profitable? Eliem Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -141.98%. Eliem Therapeutics' return on equity of -47.03% beat Enanta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eliem TherapeuticsN/A -47.03% -45.97% Enanta Pharmaceuticals -141.98%-89.02%-27.28% Which has higher earnings & valuation, ELYM or ENTA? Eliem Therapeutics has higher earnings, but lower revenue than Enanta Pharmaceuticals. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEliem TherapeuticsN/AN/A-$35.12M-$0.53-3.55Enanta Pharmaceuticals$64.81M3.85-$116.04M-$4.32-2.70 Which has more volatility & risk, ELYM or ENTA? Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Does the media favor ELYM or ENTA? In the previous week, Enanta Pharmaceuticals had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 3 mentions for Enanta Pharmaceuticals and 0 mentions for Eliem Therapeutics. Enanta Pharmaceuticals' average media sentiment score of 0.96 beat Eliem Therapeutics' score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Eliem Therapeutics Neutral Enanta Pharmaceuticals Positive Do analysts rate ELYM or ENTA? Enanta Pharmaceuticals has a consensus target price of $20.83, indicating a potential upside of 78.37%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 SummaryEnanta Pharmaceuticals beats Eliem Therapeutics on 11 of the 15 factors compared between the two stocks. Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.93M$1.06B$6.10B$10.46BDividend YieldN/A4.84%5.73%4.77%P/E Ratio-3.551.2585.5227.36Price / SalesN/A31.47609.44137.64Price / CashN/A17.6437.4661.86Price / Book0.487.6612.396.81Net Income-$35.12M-$7.71M$3.32B$276.80M7 Day Performance4.44%-0.72%0.57%0.42%1 Month Performance-7.84%24.37%10.53%7.86%1 Year Performance-65.44%-12.15%72.40%41.24% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$1.88-6.0%N/A-65.4%$55.93MN/A-3.559Gap DownHigh Trading VolumeENTAEnanta Pharmaceuticals4.0197 of 5 stars$10.96-4.6%$20.83+90.1%+0.1%$234.33M$67.64M-2.54160ZURAZura Bio3.0838 of 5 stars$3.58-7.3%$11.60+224.0%-10.8%$232.77MN/A-5.113Analyst ForecastGap DownFENCAdherex Technologies2.0074 of 5 stars$8.27-2.0%$13.33+61.2%+88.4%$230.82M$47.54M-19.6910Trending NewsAnalyst RevisionGap DownTRDAEntrada Therapeutics2.7152 of 5 stars$6.06+4.3%$25.67+323.5%-64.7%$230.52M$210.78M-3.40110CRBUCaribou Biosciences1.8745 of 5 stars$2.44+2.5%$6.67+173.2%+45.6%$227.21M$9.99M-1.37100CLLSCellectis0.6923 of 5 stars$4.17-5.7%$4.00-4.1%+116.3%$224.56M$49.22M-5.09290Gap DownSLSSELLAS Life Sciences Group1.8428 of 5 stars$2.05+2.5%$7.00+241.5%+81.7%$215.87M$1M-6.4110Options VolumeGap UpHigh Trading VolumeBDTXBlack Diamond Therapeutics3.4644 of 5 stars$3.76-1.1%$11.00+192.6%+22.1%$214.09MN/A16.3590News CoveragePositive NewsAnalyst ForecastGap UpSAVACassava Sciences2.73 of 5 stars$4.43+8.0%$2.00-54.9%-83.6%$214.01MN/A-1.7430Positive NewsGap UpEPRXEupraxia Pharmaceuticals2.6351 of 5 stars$5.87-3.0%$11.00+87.4%+143.2%$211.09MN/A-6.9129High Trading Volume Related Companies and Tools Related Companies Enanta Pharmaceuticals Alternatives Zura Bio Alternatives Adherex Technologies Alternatives Entrada Therapeutics Alternatives Caribou Biosciences Alternatives Cellectis Alternatives SELLAS Life Sciences Group Alternatives Black Diamond Therapeutics Alternatives Cassava Sciences Alternatives Eupraxia Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELYM) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
